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The filing of patents containing
DNA sequences has been
contentious since it was first
attempted two decades or so ago.
The issue has often been
polarised with companies
sometimes seeking to patent
broadly and others notably,
funders of public research and
some key scientists, wishing to
make all sequence data fully
available to all researchers.
But the climate of free access is
under increasing pressure as
universities around the world are
now setting up offices to
encourage and facilitate patent
protection of as much of their
staff’s research as possible to
generate potentially lucrative
royalty income.
A new report by the Nuffield
Council of Bioethics in London is
therefore timely in its efforts to
try to find a defendable and
pragmatic middle ground. It
hopes that the report might help
pave the way to the patenting of
genes in a way that the research
community would find acceptable
while preserving access to key
data for researchers and
protecting the investment needed
for the development of new
medicines based on genetic data.
“The aim was to produce a short
discussion paper after three or
four meetings in a matter of
months. That the process took
two years and nine meetings
testifies to the difficult and
complex nature of the issues that
were raised,” says Ian Kennedy,
chairman of the council.
The new report does not say
that patenting genes is wrong in
principle. What it concludes is that
far too many gene patents are
being granted by a system that is
failing to apply the rules strictly
enough. The purpose of patents is
to stimulate innovation for the
public good and reward people for
new inventions. “But many new
patents for human DNA are likely
to impede innovation and create
powerful monopolies capable of
charging high prices for tests and
drugs based on human genes,”
says Sandy Thomas, director of
the council. “Patents involving
human DNA should be granted
only in rare cases. They should be
the exception rather than the
norm.”
The most common objection to
the patents on gene sequences is
that genes occur naturally: they
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are there to be discovered and not
invented. The draft map of the
human genome published last
year described an estimate of
30,000 to 40,000 genes. But the
council found this argument
unpersuasive. “Isolated DNA does
not occur naturally, and without
isolating and cloning a gene, you
cannot decipher its sequence.
Moreover, the patent system has
long recognised useful
applications of discoveries as
inventions,” says Thomas.
So the report therefore
concludes that patent officers are
right to conclude that DNA can be
considered part of an invention.
But the key issue, the committee
believes, is the crucial need for a
rethink of where to draw the line
between a discovery and an
invention and to tighten up these
criteria. Patenting is a slow
process; it can take on average 44
months to get a patent granted in
Europe and 25 months in the US.
Mechanisms also exist for people
to challenge patents but these
can take years to carry out. So
there is growing pressure on the
system to to be fair and accurate
in its initial decisions if the system
is to maintain support from the
research and industrial
communities.
The report argues that it is vital
in assessing patents involving
DNA sequence that it does not
follow that all patents on all
human genes should be allowed
in all circumstances. Inventions
must pass three tests to qualify
for a patent. They must be useful,
novel and not obvious to someone
familiar with the field. To look at
how these criteria should apply to
genes, the committee
distinguished between four
different uses of DNA sequences:
in genetic tests, as research tools,
in gene therapy and for producing
therapeutic proteins.
First, genetic testing. Heated
controversy continues over an
American company called Myriad
Genetics and its patent for the
breast cancer genes BRCA1 and
BRCA2. “The company is
charging a large fee to test
patients and claiming royalties
from others who offer tests based
on the same gene,” says Thomas.
But finding a link between a gene
and a disease is not itself an
invention: it is a discovery. “And
once such a link comes to light, it
is obvious that the gene might
form the basis of a genetic test.
There is little inventive about it.
That is why we concluded that
gene patents based on claims
about diagnosis should seldom be
granted,” says Thomas.
The same reasoning should
apply to patents that are based on
claims about gene therapy, the
committee says. Once a gene has
been linked to a disease, the
notion of using it in a treatment is
obvious and shouldn’t merit the
reward of a patent. Patents should
be reserved for those who invent
safe and effective methods for
getting genes into tissues, the
report argues.
It is vital in assessing
patents involving DNA
sequence that it does not
follow that all patents on all
human genes should be
allowed in all circumstances
Also to be discouraged are
patents on genes of unknown
medical value, the committee
believes. “These days, scientists
can identify human genes by
trawling through databases of
human DNA and making ‘best
guesses’ about the biological
functions and potential uses of
the genes they find there. And
past experience suggests that
allowing speculation to pass for
actual evidence of usefulness is a
recipe for hindering research,”
says Thomas.
A salutary lesson involves the
human gene for a receptor known
as CCR5. In 1995, a US company
called Human Genome Sciences
applied to patent the gene for its
usefulness in combating viral
infections, solely on the basis of
its similarity to known DNA
sequences. Shortly after,
researchers elsewhere discovered
that the receptor was HIV’s
passport into cells. So because of
the speculative patent it holds,
Human Genome Sciences is
entitled to levy royalties from
companies that use the receptor
to look for potential HIV drugs.
But the committee is keen to
highlight what it sees as the
benefit of the patent system for
DNA sequence work. One type of
gene patent is acceptable, the
committee feels. Companies and
labs should be allowed to own the
rights to genes whose protein
products are used directly as
medicines, such as human insulin
or erythropoeitin. The information
encoded in such genes is being
used to make something of value,
and it is in the public interest to
create incentives to encourage
the costly process of developing a
medicine, it believes.
But since genes often carry the
instructions for more than one
protein, there is a caveat. The
rights to a gene should only
extend to one protein.
Most of the recommendations
are realistic and do not require
new laws. They could be achieved
by applying the existing criteria
for patents more stringently.
“Without this, we face the
prospect of more attempts to
monopolise genes, more high
prices for gene tests, and the
tying up in legal red tape of ever
more human DNA sequences,”
says Thomas.
Various bodies are now
involved in the assessment of the
ethical implications of patenting
DNA and to consider reform of
the current system. The UN,
through its Convention on
Biological Diversity signed in
1992, places strong emphasis on
the fair and equitable sharing of
benefits arising from the use of
genetic resources. The Council of
Europe has since proposed
collaborating with the EU, World
Intellectual Property Organisation,
Food and Agriculture
Organisation, World Trade
Organisation and UNESCO to
discuss a suitable alternative
system of protecting intellectual
property in relation to
biotechnology which would meet
the aims of the Convention on
Biological Diversity and global
interests. The Nuffield Council
report may be just one input that
suggests how changes to the
current patent system might be
able to help meet these goals.
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